Skip to content
Screener

Maze Therapeutics MAZE Return on invested capital

Return on invested capital at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
28.4%+1.4pp
Septerna, Inc. logo
Septerna, Inc.SEPN
-16.2%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-114.4%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
-52.9%-0.1pp
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-89.5%+48.4pp
Schrodinger logo
SchrodingerSDGR
-83.1%+94.1pp

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$48.0M-31.7%
Net income-$44.7M-32.8%
EPS (diluted)-$0.76+1.3%

Balance sheet

See full
Cash & equivalents$202.6M-23.4%
Total debt$60.4M+142%
Total equity$453.1M+72.8%
Total assets$531.6M+75.2%

Cash flow

See full
Operating cash flow-$15.1M+49.9%
CapEx$107.0K-72.8%
Free cash flow-$15.2M+50.2%

Valuation

See full
Market cap$1.51B+156%
Enterprise value$1.37B+290%

Returns & leverage

See full
Return on equity-37.3%
Debt / equity0.1×0.0×
Current ratio18.3×+4.7×

Where this comes from

Calculated from Maze Therapeutics’s reported figures.

Based on trailing twelve months.

The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 4:48 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344903

FAQ

What is Maze Therapeutics's return on invested capital?
Maze Therapeutics (MAZE) reported return on invested capital of -87.3% in Q2 2026.
What does return on invested capital mean?
Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.

Ask your AI about Maze Therapeutics's return on invested capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude